Press Releases Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Real-time Estimate Cboe BZX Other stock markets 12:55:13 2024-05-21 pm EDT			5-day change	1st Jan Change
0.815 ^USD	-0.78%		-2.36%	-38.38%

May. 14	Firefly Neuroscience Names David Johnson Executive Chairman, Following WaveDancer Merger	MT
May. 14	Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with Mindbio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enveric Biosciences Sells Cannabinoid-Related IP To Focus On Emerging Psychedelic-Inspired Drugs	May. 18	AQ
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results	May. 15	BU
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders	May. 14	BU
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids	May. 08	BU
Unlocking New Horizons: Enveric Biosciences’ Strategic Moves in Biotechnology [Microdose]	Apr. 30	PU
Enveric Biosciences : Shareholder Meeting - Form 8-K	Mar. 28	PU
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023	Mar. 26	BU
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease	Mar. 19	BU
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets	Mar. 12	BU
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds	Feb. 29	BU
Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB	Feb. 28	AQ
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property	Feb. 26	AQ
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property	Feb. 23	BU
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders	Feb. 21	BU
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series	Jan. 03	BU
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market	Dec. 29	BU
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series	Dec. 28	BU
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373	Dec. 27	BU
Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”	Dec. 20	BU
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds	Dec. 05	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Press Releases

Filters